.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Fuji
Mallinckrodt
Farmers Insurance
Cipla
Federal Trade Commission
Healthtrust
Accenture
AstraZeneca
McKesson

Generated: November 23, 2017

DrugPatentWatch Database Preview

OPTIMARK Drug Profile

« Back to Dashboard

What is the patent landscape for Optimark, and what generic Optimark alternatives are available?

Optimark is a drug marketed by Liebel-flarsheim and is included in three NDAs.

The generic ingredient in OPTIMARK is gadoversetamide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the gadoversetamide profile page.
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Liebel-flarsheim
OPTIMARK
gadoversetamide
INJECTABLE;INJECTION020937-001Dec 8, 1999RXYesYes► Subscribe► Subscribe► Subscribe
Liebel-flarsheim
OPTIMARK IN PLASTIC CONTAINER
gadoversetamide
INJECTABLE;INJECTION020976-003Dec 8, 1999RXYesYes► Subscribe► Subscribe► Subscribe
Liebel-flarsheim
OPTIMARK
gadoversetamide
INJECTABLE;INJECTION020937-004Dec 8, 1999RXYesYes► Subscribe► Subscribe► Subscribe
Liebel-flarsheim
OPTIMARK IN PLASTIC CONTAINER
gadoversetamide
INJECTABLE;INJECTION020976-004Dec 8, 1999RXYesYes► Subscribe► Subscribe► Subscribe
Liebel-flarsheim
OPTIMARK
gadoversetamide
INJECTABLE;INJECTION020937-002Dec 8, 1999RXYesYes► Subscribe► Subscribe► Subscribe
Liebel-flarsheim
OPTIMARK
gadoversetamide
INJECTABLE;INJECTION020937-003Dec 8, 1999RXYesYes► Subscribe► Subscribe► Subscribe
Liebel-flarsheim
OPTIMARK IN PLASTIC CONTAINER
gadoversetamide
INJECTABLE;INJECTION020976-002Dec 8, 1999RXYesYes► Subscribe► Subscribe► Subscribe
Liebel-flarsheim
OPTIMARK
gadoversetamide
INJECTABLE;INJECTION020975-001Dec 8, 1999RXYesYes► Subscribe► Subscribe► Subscribe
Liebel-flarsheim
OPTIMARK IN PLASTIC CONTAINER
gadoversetamide
INJECTABLE;INJECTION020976-001Dec 8, 1999RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: OPTIMARK

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Liebel-flarsheim
OPTIMARK
gadoversetamide
INJECTABLE;INJECTION020937-001Dec 8, 1999► Subscribe► Subscribe
Liebel-flarsheim
OPTIMARK
gadoversetamide
INJECTABLE;INJECTION020937-002Dec 8, 1999► Subscribe► Subscribe
Liebel-flarsheim
OPTIMARK
gadoversetamide
INJECTABLE;INJECTION020937-003Dec 8, 1999► Subscribe► Subscribe
Liebel-flarsheim
OPTIMARK
gadoversetamide
INJECTABLE;INJECTION020937-004Dec 8, 1999► Subscribe► Subscribe
Liebel-flarsheim
OPTIMARK
gadoversetamide
INJECTABLE;INJECTION020937-004Dec 8, 1999► Subscribe► Subscribe
Liebel-flarsheim
OPTIMARK
gadoversetamide
INJECTABLE;INJECTION020975-001Dec 8, 1999► Subscribe► Subscribe
Liebel-flarsheim
OPTIMARK
gadoversetamide
INJECTABLE;INJECTION020975-001Dec 8, 1999► Subscribe► Subscribe
Liebel-flarsheim
OPTIMARK
gadoversetamide
INJECTABLE;INJECTION020937-003Dec 8, 1999► Subscribe► Subscribe
Liebel-flarsheim
OPTIMARK
gadoversetamide
INJECTABLE;INJECTION020937-002Dec 8, 1999► Subscribe► Subscribe
Liebel-flarsheim
OPTIMARK
gadoversetamide
INJECTABLE;INJECTION020937-001Dec 8, 1999► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Teva
Express Scripts
Argus Health
Daiichi Sankyo
Federal Trade Commission
Fish and Richardson
Cantor Fitzgerald
Citi
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot